Ford Andrew H
Western Australian Centre for Health & Ageing (M573), Centre for Medical Research, University of Western Australia, 35 Stirling Highway, Crawley, Perth, WA 6009, Australia.
Maturitas. 2014 Oct;79(2):209-15. doi: 10.1016/j.maturitas.2014.04.005. Epub 2014 Apr 13.
Dementia affects approximately 6.5% of people over the age of 65. Whilst cognitive impairment is central to the dementia concept, neuropsychiatric symptoms are invariably present at some stage of the illness. Neuropsychiatric symptoms result in a number of negative outcomes for the individual and their caregivers and are associated with higher rates of institutionalization and mortality. A number of factors have been associated with neuropsychiatric symptoms including neurobiological changes, dementia type, and illness severity and duration. Specific patient, caregiver and environmental factors are also important. Neuropsychiatric symptoms can be broadly divided into four clusters: psychotic symptoms, mood/affective symptoms, apathy, and agitation/aggression. Neuropsychiatric symptoms tend to persist over time although differing symptom profiles exist at various stages of the illness. Assessment should take into account the presenting symptoms together with an appreciation of the myriad of likely underlying causes for the symptoms. A structured assessment/rating tool can be helpful. Management should focus on non-pharmacological measures initially with pharmacological approaches reserved for more troubling symptoms. Pharmacological approaches should target specific symptoms although the evidence-base for pharmacological management is quite modest. Any medication trial should include an adequate appreciation of the risk-benefit profile in individual patients and discussion of these with both the individual and their caregiver.
痴呆症影响着约6.5%的65岁以上人群。虽然认知障碍是痴呆症概念的核心,但神经精神症状在疾病的某个阶段总是会出现。神经精神症状会给患者及其照顾者带来一系列负面后果,并与更高的机构化率和死亡率相关。许多因素与神经精神症状有关,包括神经生物学变化、痴呆类型、疾病严重程度和病程。特定的患者、照顾者和环境因素也很重要。神经精神症状大致可分为四类:精神病性症状、情绪/情感症状、淡漠和激越/攻击行为。尽管在疾病的不同阶段存在不同的症状表现,但神经精神症状往往会随着时间持续存在。评估应考虑到呈现出的症状以及对症状背后众多可能原因的认识。结构化的评估/评分工具可能会有所帮助。管理应首先侧重于非药物措施,药物治疗方法则用于处理更棘手的症状。药物治疗方法应针对特定症状,尽管药物管理的证据基础相当有限。任何药物试验都应充分评估个体患者的风险效益概况,并与患者及其照顾者进行讨论。